AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
VolitionRx Presents Nu.Q Vet Cancer Test at AMAMS 2025 in Thailand
ByAinvest
Thursday, Jun 5, 2025 12:34 pm ET1min read
VolitionRx showcased its Nu.Q Vet Cancer Test at the Asian Meeting of Animal Medicine Specialties through two presentations. The studies explored the test's efficacy in diagnosing Canine Chronic Enteropathy versus Gastrointestinal Lymphoma and its use as a biomarker for canine nasal tumors. Collaboration with FujiFilm Vet Systems suggests potential for wider adoption in the Asian market. The test offers a less invasive, yet reliable, diagnostic alternative for these clinical scenarios.
VolitionRx Limited (NYSE AMERICAN: VNRX), a multi-national epigenetics company, showcased its Nu.Q Vet Cancer Test at the Asian Meeting of Animal Medicine Specialties (AMAMS 2025) in Thailand through two significant presentations. The studies explored the test's efficacy in diagnosing Canine Chronic Enteropathy versus Gastrointestinal Lymphoma and its use as a biomarker for canine nasal tumors.The first study, led by Dr. Masahiko Sato in collaboration with FujiFilm Vet Systems, focused on the test's ability to accurately differentiate between Canine Chronic Enteropathy and Gastrointestinal Lymphoma. This differentiation is crucial as it often involves invasive diagnostic procedures. The Nu.Q Vet Cancer Test offers a less invasive, yet reliable, diagnostic alternative. Dr. Sato, a key opinion leader in veterinary medicine, highlighted the value of the test as a diagnostic tool [1].
The second presentation examined the potential of the test as a biomarker for canine nasal tumors by evaluating plasma nucleosome concentrations. This innovative approach presents significant promise in the field of veterinary oncology, particularly in the early detection and treatment monitoring of nasal tumors in dogs. The involvement of key industry players and the promising results bolster confidence in the test's potential integration into standard veterinary practices [2].
Both presentations took place on June 5, 2025, at AMAMS 2025, reflecting Volition's commitment to advancing veterinary diagnostics and expanding its market presence in Asia. The collaboration with FujiFilm Vet Systems suggests potential for wider adoption in the Asian market.
References:
[1] https://finance.yahoo.com/news/volition-announces-two-oral-presentations-010000294.html
[2] https://www.gurufocus.com/news/2909366/volition-announces-two-oral-presentations-at-asian-meeting-of-animal-medicine-specialties-vnrx-stock-news
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet